Unknown Analyst
Analyst
Replay available
Enanta Pharmaceuticals, Inc. (ENTA) Q3 2023 Earnings Call
Enanta Pharmaceuticals, Inc. (NASDAQ: ENTA) Q3 2023 earnings conference call, held 2023-08-07. Replay captured from the company's public earnings webcast.
Hosted by
Featured presenters
Nick Gaskick
Analyst, LearRink Partners (on behalf of Roana Ruiz)
Brian Abrahams
Analyst, RBC Capital Markets
Paul Mellett
Chief Financial Officer
Dr. Jay Lulli
President and Chief Executive Officer
Dr. Tara Kiefer
Senior Vice President, New Product Strategy and Development
Jennifer Vieira
Investor Relations
Eric Joseph
Analyst, J.P. Morgan
Investor webinar replay
Watch the replay and follow the connected company analysis, news, and investor updates for Enanta Pharmaceuticals, Inc..
Replay transcript excerpt
WEBVTT 00:00:00.049 -- 00:00:05.354 Good afternoon and welcome to Enanta Pharmaceutical's fiscal third quarter 00:00:05.354 -- 00:00:09.718 financial results conference call. At this time, all participants are in listen-only 00:00:09.718 -- 00:00:14.703 mode. There will be a question and answer session at the end of the prepared remarks. 00:00:14.703 -- 00:00:18.467 Please be advised that this call is being recorded. 00:00:18.467 -- 00:00:23.872 I would now like to turn the call over to Jennifer Vieira, Investor Relations. 00:00:23.872 -- 00:00:26.380 Please go ahead. 00:00:26.380 -- 00:00:30.703 Thank you, operator, and thanks to everyone for joining us this afternoon. 00:00:30.703 -- 00:00:35.766 The news release with our fiscal third quarter 2023 financial results was 00:00:35.766 -- 00:00:39.728 issued this afternoon and is available on our website. 00:00:39.728 -- 00:00:42.630 Making formal remarks on today's call are Dr. 00:00:42.630 -- 00:00:47.633 Jay Lulli, President and Chief Executive Officer, and Paul Mellett, our Chief Financial 00:00:47.633 -- 00:00:52.349 Officer, Dr. Scott Rottinghaus, our Chief Medical Officer, And Dr. 00:00:52.349 -- 00:00:57.293 Tara Kiefer, our Senior Vice President of New Product Strategy and Development, will 00:00:57.293 -- 00:01:00.355 be available during the Q&A portion of the call. 00:01:00.355 -- 00:01:04.518 Before we begin with our formal remarks, we want to remind you that we will be making 00:01:04.518 -- 00:01:09.501 forward-looking statements, which may include our plans and expectations with respect 00:01:09.501 -- 00:01:14.264 to our research and development pipeline and financial projections, all of which involve 00:01:14.264 -- 00:01:19.603 certain assumptions and risks beyond our control that could cause our actu...